Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Extract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ampudia-Blasco, F. J.
Right arrow Articles by Carmena, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ampudia-Blasco, F. J.
Right arrow Articles by Carmena, R.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Diabetes Care 28:2983, 2005
© 2005 by the American Diabetes Association, Inc.

Letters: Observations
Letters: Observations

A Case of Lipoatrophy With Insulin Glargine

Long-acting insulin analogs are not exempt from this complication

F. Javier Ampudia-Blasco, MD1, Juan Girbes, MD2 and Rafael Carmena, MD1

1 Diabetes Reference Unit, Endocrinology Department, Clinic University Hospital, Valencia, Spain
2 Diabetes Unit, Arnau de Vilanova Hospital, Valencia, Spain

Address correspondence to Dr. F. Javier Ampudia-Blasco, Diabetes Reference Unit, Endocrinology Department, Clinic University Hospital Valencia, Avda Blasco Ibáñez, 17, 46010 Valencia, Spain. E-mail: francisco.j.ampudia{at}uv.es

Lipoatrophy as a cutaneous complication of insulin therapy became extremely rare since the introduction of recombinant human insulin. Recently, some cases of lipoatrophy were reported in association with the use of rapid-acting insulin analogs, like lispro insulin, in combination with pump therapy (1,2). If long-acting insulin analogs are exempt from this, the complications are not known.

We report the case of a 39-year-old type 1 diabetic Caucasian woman (weight 50 kg, BMI 21.4 kg/m2) with diabetes duration of 8 years. She began intensified insulin therapy with two premixed insulin injections before breakfast and dinner and regular insulin before lunch (20 IU/day, 72% neutral protamine Hagedorn insulin). In January 2004, she agreed to participate in a 6-month randomized study comparing different multiple daily insulin therapies, all using bedtime insulin glargine as basal insulin. No specific instructions about the preferred injection area for both insulins were given, but it is a common practice in our country to inject rapid-acting insulin into the abdomen and long-acting insulin into the buttock or thigh.

At follow-up, a lipoatrophic area appeared at study end in the outside, upper third of the right thigh (Fig. 1). Asking the patient about the possible causes, she recognized that she didn’t change pen needles frequently and, even more importantly, she had used the right thigh for glargine injection almost exclusively. She was prompted to avoid the right thigh for insulin injection shifting to buttock or left thigh areas and changing the area every day. However, 12 months later the lipoatrophy area persisted with the same extent.



View larger version (107K):
[in this window]
[in a new window]
  		Figure 1— Lipoatrophic area on the outside, upper part of thigh where insulin glargine was injected.

 
This case confirms that any insulin preparation, even insulin analogs, may induce lipoatrophy. Insulin glargine, a di-arginyl insulin analog, is a new long-acting insulin analog soluble at acid pH (4.0) but less soluble at neutral pH because isoelectric point is at a pH level of ~6.4–6.6. After subcutaneous injection, precipitation or crystallization of glargine at the site of injection delays absorption and prolongs the effect of insulin, allowing a peakless, nearly 24-h duration of action (3).

Insulin glargine is now being used extensively as basal insulin in both type 1 and type 2 diabetes. To our knowledge, this is the first description of lipoatrophy induced by insulin glargine. Certainly, the frequent use (up to 14 times) of the same pen needle and the repeated injection into the same area were relevant to the appearance of lipoatrophy in this case. Under such circumstances, we did not know if in this case the injection of an acid insulin solution and the subsequent formation of crystals in the subcutaneous tissue could have played a role in lipoatrophy formation. It has been suggested earlier that lipoatrophy results from a local immune reaction to insulin crystals (4). The inflammatory response includes local hyperproduction of tumor necrosis factor {alpha} from macrophages that led to dedifferention of adipocytes (lipoblastoma-like lipoatrophy) (4).

In conclusion, daily pen needle change and frequent switching of injection area are even more important with insulin glargine to avoid lipoatrophy.

References

  1. Griffin ME, Feder A, Tamborlane WV: Lipoatrophy associated with lispro in insulin pump therapy (Letter). Diabetes Care24 :174 ,2001[Free Full Text]
  2. Ampudia-Blasco FJ, Hasbum B, Carmena R: A new case of lipoatrophy with lispro insulin in insulin pump therapy: is there any insulin preparation free of complications (Letter)? Diabetes Care26 :953 –954,2003[Free Full Text]
  3. Lepore M, Pampanelli S, Fanelli C, Porcellati F, Bartocci L, Di Vincenzo A, Cordoni C, Costa E, Brunetti P, Bolli GB: Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes49 :2142 –2148,2000[Abstract/Free Full Text]
  4. Jermendy G, Nádas J, Sápi Z: "Lipoblastoma-like" lipoatrophy induced by human insulin: morphological evidence for local dedifferentiation of adipocytes (Letter)? Diabetologia43 :955 –956,2000[Medline]

Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?



This Article
Right arrow Extract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ampudia-Blasco, F. J.
Right arrow Articles by Carmena, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ampudia-Blasco, F. J.
Right arrow Articles by Carmena, R.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum